Onconetix Registers 22M Shares for Resale, Shifts Focus to Prostate Cancer Diagnostic

TL;DR

**Onconetix is dumping 22 million shares on the market, abandoning its FDA-approved drug, and betting everything on a prostate cancer diagnostic — proceed with extreme caution.**

AI Summary

Onconetix, Inc. (ONCO) filed an S-1 on November 4, 2025, registering 22,071,891 shares of common stock for resale by Selling Stockholders. This includes up to 14,828,006 shares from Series D preferred stock and warrants issued in a September 22, 2025 private placement, and up to 7,002,371 shares from Series E preferred stock and warrants issued in an October 1, 2025 private placement. Additionally, 241,514 shares issued to Altos Venture AG in connection with a December 15, 2023 Share Exchange Agreement are included. The company will not receive proceeds from the resale of these shares, only from the cash exercise of PIPE Warrants. Onconetix has shifted its focus to commercializing Proclarix, an in vitro diagnostic test for prostate cancer acquired through Proteomedix AG on December 15, 2023. The company has abandoned commercialization of ENTADFI, an FDA-approved BPH treatment, due to time, resource, cash runway, and indebtedness constraints, fully impairing ENTADFI assets by June 30, 2024, and terminating three employees involved with the program on April 30, 2024. The last reported sale price of ONCO common stock on Nasdaq was $3.16 per share on November 3, 2025. The company reported a net loss of $(9,716) for the three months ended March 31, 2025, compared to $(11,119) for the same period in 2024, and a net loss of $(58,897) for the year ended December 31, 2024.

Why It Matters

This S-1 filing signals a significant dilution risk for existing ONCO investors as 22,071,891 shares are registered for resale, representing a substantial portion of the company's market capitalization given the $3.16 share price. The strategic pivot away from ENTADFI, an FDA-approved product, towards Proclarix, a European-approved diagnostic, indicates a critical re-evaluation of the company's commercialization strategy and cash burn. This shift could impact employees previously involved with ENTADFI and potentially alter the competitive landscape in prostate cancer diagnostics, where Proclarix aims to reduce unnecessary biopsies. The company's ability to successfully commercialize Proclarix, especially through its license agreement with LabCorp in the U.S., will be crucial for its future viability.

Risk Assessment

Risk Level: high — The risk level is high due to the significant potential for dilution from the resale of 22,071,891 shares by Selling Stockholders, which could depress the stock price from its November 3, 2025 price of $3.16. Furthermore, the company has abandoned commercialization of its FDA-approved ENTADFI product, fully impairing its assets by June 30, 2024, and is now solely focused on Proclarix, a product approved in the EU but anticipated to be marketed in the U.S. as a lab developed test, introducing regulatory and commercialization uncertainties.

Analyst Insight

Investors should exercise extreme caution and consider the immediate dilution risk from the 22,071,891 shares registered for resale. Given the abandonment of ENTADFI and the pivot to Proclarix, investors should thoroughly evaluate Onconetix's cash runway, its ability to secure U.S. market acceptance for Proclarix, and the competitive landscape in prostate cancer diagnostics before making any investment decisions.

Financial Highlights

debt To Equity

N/A

revenue

N/A

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

$(9,716)

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Key Numbers

• 22,071,891 — Shares of Common Stock (Total shares registered for resale by Selling Stockholders, indicating potential dilution)
• 14,828,006 — Shares of Common Stock (Shares from Series D preferred stock and warrants, representing 150% of initially issuable shares from a September 22, 2025 private placement)
• 7,002,371 — Shares of Common Stock (Shares from Series E preferred stock and warrants, representing 150% of initially issuable shares from an October 1, 2025 private placement)
• 241,514 — Shares of Common Stock (Shares issued to Altos Venture AG in a December 15, 2023 Share Exchange Agreement)
• $3.16 — Common Stock Price (Last reported sale price on Nasdaq on November 3, 2025, providing a benchmark for potential resale impact)
• $(9,716) — Net Loss (For the three months ended March 31, 2025, indicating ongoing operational losses)
• $(58,897) — Net Loss (For the year ended December 31, 2024, highlighting significant annual losses)
• 1:85 — Reverse Stock Split Ratio (Effected on June 13, 2025, impacting historical share and per-share data)
• 3 — Years (Expiration period for Series D and Series E Warrants from issuance date)
• 50% — Percentage (Estimated percentage of biopsies with elevated PSA that are negative or clinically insignificant, highlighting Proclarix's market opportunity)

Key Players & Entities

• Onconetix, Inc. (company) — Registrant and issuer of common stock
• Karina M. Fedasz (person) — Interim Chief Executive Officer and Interim Chief Financial Officer
• Ellenoff Grossman & Schole LLP (company) — Legal counsel for Onconetix, Inc.
• Altos Venture AG (company) — Recipient of 241,514 shares of Common Stock in a December 15, 2023 Share Exchange Agreement
• Proteomedix AG (company) — Company acquired by Onconetix, bringing Proclarix product
• Laboratory Corporation of America (company) — Third-party partner for U.S. marketing of Proclarix
• SEC (regulator) — Securities and Exchange Commission
• $3.16 (dollar_amount) — Last reported sale price of ONCO Common Stock on November 3, 2025
• $0.00001 (dollar_amount) — Par value per share of Onconetix Common Stock
• $3.6896 (dollar_amount) — Initial exercise price of Series D Warrants and conversion price of Series D Preferred Stock

FAQ

Risk Factors

• Reliance on PIPE Financings [high — financial]: The company has recently completed private placements (PIPEs) of Series D and Series E preferred stock and warrants. These financings are crucial for funding operations and commercialization efforts, but they also introduce significant dilution and potential future selling pressure on the common stock.
• Abandonment of ENTADFI Program [high — operational]: Onconetix has fully impaired assets related to its ENTADFI program due to resource constraints, cash runway limitations, and indebtedness. This decision led to the termination of three employees and signifies a strategic pivot, but also represents a significant write-off and a setback in product development.
• Significant Net Losses [high — financial]: The company reported a net loss of $(9,716) for the three months ended March 31, 2025, and a net loss of $(58,897) for the year ended December 31, 2024. These ongoing losses indicate a need for continued funding and raise concerns about long-term financial sustainability.
• Proclarix Commercialization Risk [medium — market]: The company's future success hinges on the commercialization of Proclarix, an in vitro diagnostic test for prostate cancer. The market opportunity is significant, with an estimated 50% of biopsies with elevated PSA being negative or clinically insignificant, but competition and market adoption risks remain.
• Potential Dilution from Resale Shares [medium — financial]: The S-1 registers 22,071,891 shares for resale, including shares from recent Series D and E preferred stock and warrants. This large number of shares could exert downward pressure on the stock price if sold in significant quantities, especially given the current market price of $3.16.
• Warrant Exercise and Dilution [medium — financial]: The S-1 includes shares issuable upon exercise of warrants from the Series D and E private placements. While warrant exercises can provide cash to the company, they also lead to further dilution of existing shareholders.
• Diagnostic Test Regulatory Pathway [medium — regulatory]: As an in vitro diagnostic test, Proclarix will be subject to regulatory review and approval processes, likely by the FDA. Delays or failures in obtaining necessary approvals could significantly impact commercialization timelines and market entry.
• Indebtedness Constraints [low — financial]: The company cited indebtedness as a constraint contributing to the abandonment of the ENTADFI program. Existing or future debt obligations could continue to limit operational flexibility and strategic options.

Industry Context

The in vitro diagnostics (IVD) market, particularly in oncology, is highly competitive and driven by technological innovation and the demand for more accurate and personalized diagnostic tools. Companies are focusing on developing tests that can improve early detection, prognosis, and treatment selection. Regulatory hurdles and reimbursement policies are significant factors influencing market access and commercial success.

Regulatory Implications

As Onconetix shifts its focus to Proclarix, an IVD test, it will face rigorous regulatory scrutiny from bodies like the FDA. Successful navigation of the regulatory pathway is critical for market entry and commercial viability. The company's past experience with the ENTADFI program, which was FDA-approved but later abandoned due to business constraints, highlights the complexities of bringing medical products to market.

What Investors Should Do

1. Monitor Proclarix Commercialization Progress
2. Assess Dilution Impact
3. Evaluate Financial Health and Cash Runway
4. Understand the Competitive Landscape for Proclarix
5. Review Warrant Terms and Potential Exercise

Key Dates

• 2025-11-04: S-1 Filing — Registers a large number of shares for resale, signaling potential dilution and providing an updated view of the company's capital structure and strategic direction.
• 2025-10-01: Series E Private Placement — Issuance of Series E preferred stock and warrants, contributing to the shares registered for resale and providing capital for operations.
• 2025-09-22: Series D Private Placement — Issuance of Series D preferred stock and warrants, contributing to the shares registered for resale and providing capital for operations.
• 2025-06-13: Reverse Stock Split — A 1:85 reverse stock split was effected, impacting historical share counts and per-share data, potentially to meet exchange listing requirements.
• 2024-06-30: ENTADFI Assets Fully Impaired — Marks the official abandonment of the ENTADFI program due to financial and resource constraints, leading to significant asset write-downs.
• 2023-12-15: Share Exchange Agreement with Proteomedix AG — Acquisition of Proteomedix AG, including the Proclarix diagnostic test, marking a strategic shift towards commercializing this product.

Glossary

S-1 Filing

A registration statement filed with the U.S. Securities and Exchange Commission (SEC) by companies planning to offer securities to the public. It contains detailed information about the company's business, financial condition, and management. (This filing details the shares being registered for resale and provides updated financial and operational information for investors.)

Selling Stockholders

Individuals or entities who own shares of a company's stock and intend to sell them to the public. In this case, they are selling shares previously acquired through private placements or other agreements. (The S-1 is filed to allow these stockholders to legally resell their shares, potentially impacting the stock's supply and price.)

PIPE Financing

Private Investment in Public Equity. This is a way for public companies to raise capital by selling stock or convertible securities directly to institutional investors or accredited investors. (Onconetix has recently utilized PIPE financings (Series D and E) to raise capital, which are now being registered for resale.)

Warrants

A type of security that gives the holder the right, but not the obligation, to purchase a company's stock at a specified price (the exercise price) before a certain expiration date. (Warrants issued in the Series D and E PIPE financings are included in the S-1 for resale, and their exercise could provide cash to the company.)

In Vitro Diagnostic Test

A medical device used to perform tests on samples such as blood or tissue taken from the human body to diagnose diseases or conditions. (Proclarix, Onconetix's primary focus, is an in vitro diagnostic test for prostate cancer.)

Asset Impairment

A reduction in the carrying value of an asset on a company's balance sheet when its fair value is less than its book value. This often occurs when a project is abandoned or underperforms. (Onconetix fully impaired its ENTADFI assets, indicating the program's discontinuation and a significant financial write-off.)

Reverse Stock Split

A corporate action in which a company reduces the number of its outstanding shares by consolidating them. For example, a 1:85 reverse split means every 85 old shares become one new share. (Onconetix effected a 1:85 reverse stock split on June 13, 2025, which impacts historical share data and may have been done to meet stock exchange listing requirements.)

BPH Treatment

Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland. A BPH treatment aims to alleviate the symptoms associated with this condition. (ENTADFI was an FDA-approved treatment for BPH that Onconetix has abandoned.)

Year-Over-Year Comparison

Information regarding a prior S-1 filing or comparable period for comparison is not available in the provided context. However, the company's strategic shift from ENTADFI to Proclarix, evidenced by the impairment of ENTADFI assets and the focus on the diagnostic test, represents a significant change in business direction. The recent PIPE financings and the large number of shares being registered for resale indicate a need for capital and potential future dilution, contrasting with any prior periods where such immediate resale pressures might not have been present.

Key Financial Figures

• $0.00001 — or “Onconetix”), par value $0.00001 per share (the “Common Stock&rdqu
• $3.6896 — arrant has an initial exercise price of $3.6896 and the Series E Warrant has an initial
• $3 — arrant has an initial exercise price of $3.8576, subject to adjustment, and will e
• $3.16 — Capital Market on November 3, 2025 was $3.16 per share. We recommend that you obtain
• $0.3 m — , the Company had cash of approximately $0.3 million, a working capital deficit of app
• $11.8 million — orking capital deficit of approximately $11.8 million and an accumulated deficit of approxima
• $128.1 million — an accumulated deficit of approximately $128.1 million. During the six months ended June 30, 2
• $3.4 million — 0, 2025, the Company used approximately $3.4 million in cash for operating activities. In ad
• $6.2 million — ’s cash balance was approximately $6.2 million. The Company believes that its current
• $17.9 million — ”), it may be able to raise up to $17.9 million in gross proceeds remaining under the E

Filing Documents

• ea0263314-s1_onconetix.htm (S-1) — 422KB
• ea026331401ex23-1_onconetix.htm (EX-23.1) — 2KB
• ea026331401ex23-2_onconetix.htm (EX-23.2) — 2KB
• ea026331401ex-fee_onconetix.htm (EX-FILING FEES) — 15KB
• image_001.jpg (GRAPHIC) — 13KB
• 0001213900-25-106177.txt ( ) — 581KB
• ea026331401ex-fee_onconetix_htm.xml (XML) — 6KB

RISK FACTORS

RISK FACTORS 6 PIPE FINANCINGS 8

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 17 SELLING STOCKHOLDERS 25 PLAN OF DISTRIBUTION 30 EXPERTS 32 LEGAL MATTERS 32 WHERE YOU CAN FIND MORE INFORMATION 32 i ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-1 that we filed with the Securities and Exchange Commission (the “SEC”) using a “shelf” registration process for the delayed or continuous offering and sale of securities pursuant to Rule 415 under the Securities Act. This prospectus generally describes Onconetix, Inc. and our Common Stock. The Selling Stockholders may use the shelf registration statement to sell up to an aggregate of up to 22,071,891 shares of our Common Stock from time to time through any means described in the section entitled “ Plan of Distribution .” We will receive the proceeds from any exercise of the PIPE Warrants for cash, but not from the net exercise of PIPE Warrants on a cashless basis or from the resale of any shares of Common Stock by the Selling Stockholders pursuant to this prospectus or the sale of the shares of Common Stock issuable upon the exercise the PIPE Warrants. However, we will pay the expenses, other than underwriting discounts and commissions, associated with the sale of shares pursuant to this prospectus. We and the Selling Stockholders, as applicable, may deliver a prospectus supplement with this prospectus, to the extent appropriate, to update the information contained in this prospectus. The prospectus supplement may also add, update or change information included in this prospectus. You should read both this prospectus and any applicable prospectus supplement, together with additional information described below under the captions “ Where You Can Find More Information ” and “ Incorporation of Certain Information by Reference .” No offer of these securities will be made in any jurisdiction where the offer is not permitted. You should rely only on the